(1%) moved out of Los Angeles County and could not be interviewed in person, and 21 (2%) were lost to follow-up.
One control subject was individually matched by birth date (within 3 years), parity (nulliparous vs parous) and neighbourhood to each of the 744 young breast cancer patients who completed the interview. Control subjects were selected from housing units in a pre-defined walk pattern in the neighbourhood where the case lived at the time of her breast cancer diagnosis. The response rate among eligible controls was 79% based on the total number of controls we attempted to recruit in order to recruit 744 successfully.
A total of 1579 (67%) of 2373 eligible patients aged 55Ð64 years completed the interview. Physicians recommended against our contacting 128 (5% of eligible subjects) patients, 419 (18%) patients refused to be interviewed, 230 (10%) patients were too ill or had died and we were unable to locate 17 (< 1%) patients.
One control subject was individually matched to 1506 of the 1579 interviewed breast cancer patients on birth date (within 3 years) and neighbourhood of residence. Control recruitment was handled in the same manner as for the study of younger women. We were unable to identify and interview an eligible control for the remaining 73 case subjects. The response rate among eligible control subjects was 80%.
Demographics
Detailed information regarding demographic characteristics and reproductive histories as well as other known or suspected breast cancer risk factors was obtained by face-to-face interview with each subject. For each case and control pair (and for unmatched case patients in the study of older women), a reference date was created that was the date 12 months before the index patientÕs breast cancer diagnosis. Information obtained by interview includes only those exposures that occurred before the reference date.
Alcohol consumption
The participants were queried about the number of drinks of beer, wine and liquor that they consumed per week on average at ages 18, 25 and the reference age (women aged 40 years or younger) and at ages 25, 40 and the reference age (women aged 55Ð64). Results pertaining to alcohol consumption before the reference age added little information and are not shown. We calculated the average number of grams of alcohol consumed per day as the number of drinks per day for each type of alcoholic beverage multiplied by the estimated grams of alcohol in each beverage, which we assumed to be 12.8 for one serving of beer, 10.9 for one 4 oz glass of wine and 15.0 for one mixed drink (USDA, 1986) .
Exclusions
For the purposes of this study, we excluded 11 case patients and 16 control subjects from the study of younger women because the women were no longer menstruating, and we excluded 13 case patients and 14 control subjects who did not know their family history of breast cancer because they had been adopted. A total of 720 case patients and 714 control subjects remained in the study of pre-menopausal women. In addition, we excluded 419 case patients (of the 1579 matched and unmatched case patients) and 415 control subjects from the study of older women for the following reasons: premenopausal (still menstruating and not using hormone-replacement therapy: 58 case patients and 51 control subjects), unknown age at menopause (usually hysterectomy without bilateral oophorectomy: 352 case patients and 360 control subjects) or incomplete information on family history, education, alcohol consumption, pregnancies, breastfeeding or weight (nine case patients and four control subjects). A total of 1160 case patients and 1091 control subjects remained in the study of post-menopausal women.
ER and PR status
CSP abstracts which include copies of the patientsÕ pathology reports were reviewed for ER and PR status (positive or negative) for each breast cancer patient in the two studies. Medical and pathology records were requested and reviewed at the hospital of diagnosis if the information was not included in the CSP records for the patient. In both studies, for over 50% of the women who had missing receptor status data, the charts were located but results of the receptor assays, if done, were not in the record. The chart was unavailable, generally due to destruction or hospital closure, for about one-third of the women with missing data. ER or PR status, but not both, was available for about 10% of the women with missing data.
Of the 720 premenopausal patients with complete interview information, we retrieved ER status for 441 (61%), PR status for 425 (59%) and joint ER/PR status for 424 (59%). A total of ten patients had ER-positive tumours and seven had ER-negative tumours but were missing PR status and one patient had a PRpositive tumour but was missing ER status. We have included 405 case patients in the statistical analyses whose tumours were known to be ER-positive/PR-positive, ER-positive/PR-negative or ERnegative/PR-negative [there were too few women with ER-negative/PR-positive tumours (n = 19) to permit useful analyses], 296 women with unknown tumour ER or PR status and 714 control subjects.
We retrieved ER status for 805 (69%), PR status for 760 (66%) and joint ER/PR status for 760 (66%) of the 1160 postmenopausal patients with complete interview information included in the study of women 55Ð64 years of age. A total of 34 women had ER-positive tumours and 11 had ER-negative tumours but were missing PR status, and no women had PR status but were missing ER status. We included 736 case patients whose tumours were known to be ER-positive/PR-positive, ER-positive/PR-negative, or ERnegative/PR-negative [there were too few women with ER-negative/PR-positive tumours (n = 24) to permit useful analysis], 400 women with unknown tumour ER or PR status, and 1091 control subjects in the statistical analyses.
Statistical analyses
We compared the risk factor distributions for patients with known ER and PR status to those of patients whose ER and PR status was unknown using the χ 2 test. ORs and 95% CIs were calculated to estimate the breast cancer risk associated with alcohol consumption using unconditional logistic regression methods within joint ER and PR status subgroups using four separate models as follows: ER-positive/PR-positive vs controls, ER-positive/PRnegative vs controls, ER-negative/PR-negative vs controls, and ER unknown/PR unknown vs controls. Pair matching was not retained in the analyses in order to maximize the number of subjects to be included in the analyses. The results were not materially different when the matching was retained. We used the twosided P-value associated with the coefficient fit to the median value of each category of the variable to test for trend in effect across categories of a risk factor. We used polytomous logistic regression analysis to test for heterogeneity in the effect of alcohol consumption as a continuous variable across response functions of each of the hormone receptor status subgroups, with the control subjects serving as the reference group. SAS statistical software was used to perform all statistical analyses (SAS Institute, Cary, NC, USA). We included the matching variables [age at reference year (continuous variable) and socio-economic status (five categories based on census tract of residence)] as covariates in the multivariate models for both studies. For premenopausal women, we also included as categorical variables the following factors: age at menarche (< 12, 12, 13, ³ 14 years), age at first full-term pregnancy (never, < 20, 20Ð24, 25Ð29, ³ 30 years), number of full-term pregnancies (0, 1, 2, 3, ³ 4), lifetime months of breastfeeding (0, 1Ð6, 7Ð15, ³ 16), years of use of oral contraceptives (0, 1Ð4, 5Ð9, ³ 10), average hours per week of physical activity after menarche (0, 0.1Ð0.7, 0.8Ð1.6, 1.7Ð3.7, ³ 3.8) and first-degree family history of breast cancer (yes/no).
For postmenopausal women, we included as categorical variables in all multivariate models age at menarche (< 12, 12, 13, ³ 14 years), age at first full-term pregnancy (never, < 20, 20Ð24, 25Ð29, ³ 30 years), number of full-term pregnancies (0, 1, 2, 3, ³ 4), lifetime months of breastfeeding (0, 1Ð3, 4Ð6, 7Ð15, ³ 16), age at menopause (< 45, 45Ð49, 50Ð54, ³ 55 years), use of oestrogen-only hormone-replacement therapy (0, 1Ð12, 13Ð72, 73Ð120, ³ 121 months), use of combined oestrogen and progestin hormone-replacement therapy (0, 1Ð12, 13Ð72, 73Ð120, ³ 121 months), body-mass index (BMI) at the reference date (< 21.8, 21.8Ð23.9, 24.0Ð27.3, ³ 27.4 kg/m 2 ), physical activity (a combination variable based on average MET-hours (the ratio of the metabolic rate associated with a given activity to the resting metabolic rate) per week (MH) of activity before/after age 40: 0/0, low/low (at least one is > 0), low/high, high/low, high/high, where low is < 17.6, and high is ³ 17.6 MH), education (less than high school, high school, partial college, college or graduate/professional training) and first-degree family history of breast cancer (yes/no).
RESULTS
As expected, a greater proportion of post-menopausal than premenopausal patients had tumours that expressed both ER and PR, while twice the proportion of pre-menopausal compared with postmenopausal patients had tumours that expressed neither ER nor PR ( Table 1 ). Tumours that expressed PR but not ER were rare in both groups.
In general, the distributions of various patient factors were not different between the group of patients for whom receptor status was ascertained and the group with missing receptor status information (Table 2) . However, we observed that a greater proportion of patients with unknown than with known hormone-receptor status had in situ tumours, probably due to insufficient tissue for the receptor assays. Among premenopausal patients with unknown receptor status, the proportion with in situ disease was fourfold greater than in those with disease of known receptor status. Among postmenopausal breast cancer patients, the proportion of in situ cases with unknown receptor status was nearly tenfold greater. We also observed that a greater proportion of premenopausal and postmenopausal patients with missing receptor status had a first-degree family history of breast cancer than did patients whose receptor status was ascertained.
Among premenopausal women with known receptor status, alcohol consumption was generally unrelated to risk of breast cancer regardless of receptor type (Table 3) . Because the premenopausal women consumed fairly low levels of alcohol, the highest category of consumption in these analyses was 14 g of alcohol per day or more (approximately one drink). An association of alcohol consumption with risk of breast cancer was observed, however, among cases with unknown receptor status.
Among post-menopausal women, alcohol consumption was associated more with increased risk of ER-positive/PR-positive breast cancer than with tumours of other receptor type (Table 3) . Women who consumed at least 27 g/day on average (approximately two drinks) in the recent past experienced more than a 75% increase in risk of ER-positive/PR-positive breast cancer. We obtained similar findings for alcohol consumption at age 40 and for maximum alcohol consumption (the maximum of ages 25, 40 and the reference age) (results not shown). The results were not materially different when analysed for invasive tumours only (not shown). The alcohol coefficients compared across receptor status subgroups showed no statistically significant differences in polytomous logistic regression analyses with alcohol consumption modelled as a continuous variable. a There were too few women with ER-/PR+ tumours to permit useful analysis (see methods). b Odds ratios adjusted for age at reference year, socioeconomic status, education, age at menarche, age at first full-term pregnancy, parity, lifetime months of breastfeeding, physical activity and family history. In the analysis that included pre-menopausal women, years of use of oral contraceptives was also included in the multivariate models. In the analysis that included postmenopausal women, age at menopause, oestrogen-only replacement therapy, combined oestrogen and progestin-replacement therapy and BMI were also included in the multivariate models (see Methods).
We evaluated potential interactions of alcohol consumption with BMI and with ostrogen-replacement therapy (ERT) use for ERpositive/PR-positive tumours among postmenopausal women, because these breast cancer risk factors also represent oestrogen exposures (Table 4) . We found that risk of ER-positive/PR-positive breast cancer was increased among the heaviest women (women in the ÔhighÕ BMI category) regardless of alcohol consumption level. We observed a 2.5-fold increase in ER-positive/PR-positive risk of breast cancer among heavier women who consumed at least 14 g of alcohol per day on average in the recent past compared to thinner women who did not consume alcohol. Among thinner women, consumption of 14 g of alcohol per day was associated with about a 50% increase in risk of ER-positive/PR-positive tumours compared to non-drinkers. Because the increase in risk of breast cancer across levels of alcohol intake was similar for the low and high BMI groups, evidence of effect modification by BMI for ER-positive/PR-positive breast cancer was not compelling. In a similar analysis, we observed no evidence of effect modification by ERT use of the association of alcohol consumption with ER-positive/PR-positive breast cancer.
DISCUSSION
We observed an increased risk of ER-positive/PR-positive breast cancer among postmenopausal women who reported consumption of high levels of alcohol (> 27 g/day). Alcohol consumption was not associated with other hormone receptor subtypes postmenopausally and was generally not related to risk of any specific subtype among premenopausal patients. These results are generally consistent with those from a large case-control study conducted in New York, USA (Nasca et al, 1994) , which included more than 1100 premenopausal and postmenopausal patients with breast cancer. In that study, Nasca and colleagues reported an increased risk of ER-positive, but not ER-negative, breast cancer at the highest levels of alcohol consumption. However, premenopausal and postmenopausal patients were combined and results for PR status were not presented. Five other studies have examined alcohol consumption in relation to risk of breast cancer by tumour hormone receptor status with highly mixed results: two reported no association of alcohol with tumour ER status (Cooper et al, 1989) or with joint ER/PR status (Yoo et al, 1997) , one reported positive associations of alcohol with ER-positive and ERnegative tumours (McTiernan et al, 1986) , one reported a modest increase in risk of ER-negative breast cancer with alcohol consumption (Holm et al, 1989) , and one reported a positive association of alcohol consumption with risk of ER-negative/PR-negative breast cancer . All of the previous studies except one presented the alcoholÐreceptor status results for both premenopausal and postmenopausal women combined. Previously reported findings that suggested an interaction between alcohol and BMI, and between alcohol and ERT use, within receptor status subgroups (Gapstur et al, 1995) were not replicated in our study.
Substantial epidemiological evidence supports an association of even modest alcohol consumption (one drink per day) with increased risk of breast cancer (Longnecker, 1994) . In addition, results from experimental and cross-sectional data suggest that acute and chronic alcohol consumption increase endogenous oestrogen levels of both premenopausal and postmenopausal women (Mendelson et al, 1981 (Mendelson et al, , 1987 (Mendelson et al, , 1989 ; Teoh et al, 1988; Katsouyanni et al, 1991; Gavaler et al, 1993; Reichman et al, 1993; Dorgan et al, 1994; Hankinson et al, 1995) . Overall, this evidence combined with results of a prospective study of endogenous oestrogens and postmenopausal breast cancer indicate that the effect of alcohol on breast cancer risk may be mediated by oestrogen. However, analysis of data from the same prospective study revealed no clear associations between endogenous oestrogen levels and breast tumour hormone receptor status , raising questions about the mechanisms underlying the association of alcohol consumption and ER-positive/PR-positive breast tumours. Studies such as the one presented here may help clarify whether hormone receptor-positive and hormone receptor-negative breast tumours represent different stages in the progression of the disease or two distinct diseases with distinct aetiologies. The scientific literature includes evidence that can be interpreted to support either of these theories (Mobbs et al, 1987; Tani et al, 1988; Habel and Stanford, 1993; . Our finding that alcohol is more strongly associated with ER-positive/PR-positive risk of breast cancer among postmenopausal women supports the theory that hormone receptor status defines distinct diseases rather than different stages of the same disease.
This was the largest study to date to evaluate the association between alcohol consumption and risk of breast cancer by ER or PR type. Although generalization of findings from this study may be limited by the somewhat low ER and PR status recovery rates, it seems unlikely that the reasons for missing receptor status would have been related to receptor subtype or alcohol consumption patterns of the patients, especially since the majority of missing data was due to hospital policy (i.e. the destruction of charts inactive for over 7 years). Also, the distributions of most other breast cancer risk factors were generally similar for patients with known and unknown ER and PR status, and were therefore unlikely to introduce serious bias in the estimates derived from multivariate analyses. Another concern is that the hormone receptor status assays were performed in several different laboratories. However, results of two large European collaborative studies of steroid receptor distribution demonstrated that receptor assays were remarkably consistent across laboratories (Romain et al, 1995 (Romain et al, , 1996 . In addition, the ER/PR distributions for both premenopausal and postmenopausal women in the present study are consistent with distributions reported from other studies (Bland et al, 1981; Thorpe, 1988; Potter et al, 1995) .
In summary, these data suggest that alcohol may preferentially increase risk of ER-positive/PR-positive breast cancer in postmenopausal women, and that the association is not modified by BMI or ERT use. Although these findings support the hypothesis of an oestrogen-mediated effect of alcohol consumption on risk of breast cancer, further research is needed to determine whether the effects of alcohol consumption are mediated through interaction with steroid hormone receptors or through some other, possibly non-oestrogenic, pathway.
